Skip to main content

Bright Minds Biosciences Inc. (DRUG)

NASDAQ: DRUG · IEX Real-Time Price · USD
0.06 (1.43%)
At close: Dec 3, 2021 4:00 PM
-0.30 (-7.57%)
After-hours:Dec 3, 2021 7:47 PM EST
Market Cap46.09M
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out11.83M
EPS (ttm)-0.74
PE Ration/a
Forward PEn/a
Ex-Dividend Daten/a
Previous Close3.84
Day's Range3.71 - 4.14
52-Week Range3.61 - 8.95
Price Targetn/a
Earnings Daten/a

About DRUG

Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The ...

CountryUnited States
Stock ExchangeNASDAQ
Ticker SymbolDRUG
Full Company Profile


Bright Minds Biosciences Provides Scientific Update on its Novel 5-HT2A Psychedelic Program for the Treatment of Ment...

— Hundreds of de novo patentable psychedelic-based compounds created through discovery program —

4 days ago - GlobeNewsWire

Bright Minds Biosciences: Newest Psychedelics Company To Join The Nasdaq

Wall Street is welcoming yet another company working with psychedelic molecules for mental health and neurological treatments. Bright Minds Biosciences (CSE:DRUG) received approval on Wednesday to effec...

1 month ago - Benzinga

Bright Minds Biosciences Commences Trading on the Nasdaq Under the Ticker Symbol “DRUG”

VANCOUVER, British Columbia, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing...

1 month ago - GlobeNewsWire